drugset / Trial / NCT03618602
Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients
Phase 1
Unknown
30 enrolled
Shanghai Theorion Pharmaceutical Co Ltd.
Shanghai Institute of Materia Medica, Chinese Academy of Sciences · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics, and efficacy of Bisthianostat in refractory or recurrent multiple myeloma patients.
Timeline
- Start
- 2018-04-25
- Primary completion
- 2020-04
- Completion
- 2020-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bisthianostat | Small molecule | 100 mg | Oral |
| Subject | Bisthianostat | Small molecule | 200 mg | Oral |
| Subject | Bisthianostat | Small molecule | 400 mg | Oral |
| Subject | Bisthianostat | Small molecule | 600 mg | Oral |